Shots:
- The acquisition will integrate AmpTec’s PCR-based mRNA technology with Merck’s expertise in lipids manufacturing, providing combine offering across mRNA value chain
- The deal will expand Merck’s capabilities to develop & manufacture mRNA for use in vaccines, treatments, and diagnostics applicable in COVID-19 and many other diseases. Additionally, AmpTech’s diagnostic business focusing on customized long RNAs and DNAs for IVDs, complements existing Merck’s portfolio
- The addition of AmpTech’s PCR-based technology to Merck allow the companies to offer innovative technologies, products, and services, advancing life-enhancing therapies
Click here to read full press release/ article | Ref: Merck KGaA | Image: Glassdoor
The post Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics first appeared on PharmaShots.
